An Integrated, Innovative Solution for Liver Disease Diagnosis, Treatment and Medium-to-Long Term Follow-Up: Enhancing Chronic Liver Disease Management Capabilities
Shanghai, China — November 5, 2025 — GE HealthCare China and Hisky Medical (China) today announced the signing of a strategic memorandum of understanding (MOU) at the 8th China International Import Expo (CIIE), marking a significant step toward transforming liver disease care across China. The collaboration aims to co-develop integrated, data-driven diagnostic and treatment solutions for chronic liver disease — a condition affecting an estimated 400 million people in China.
Addressing a Growing Public Health Challenge
Chronic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), has emerged as a major health concern in China. According to the 2024 Report on Epidemiology and Disease Burden of Liver Diseases in China, NAFLD affects over 200 million individuals, with more than 25% of patients under the age of 30. The national prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has reached 31.5% and continues to rise, often in conjunction with comorbidities such as type 2 diabetes and cardiovascular disease.
A Comprehensive, Technology-Driven Approach
The partnership between GE HealthCare and Hisky Medical is structured around two strategic pillars: clinical integration and research innovation.
Clinical Integration: The collaboration will combine Hisky Medical’s iLivTouch® non-invasive liver assessment system — which provides quantitative metrics such as Liver Stiffness Measurement (LSM), Ultrasound Attenuation Parameter (UAP), and the Liver Inflammation Index (LIID) — with GE HealthCare’s advanced ultrasound and intelligent imaging platforms. This integration aims to streamline the full care pathway from early screening and diagnosis to treatment planning and long-term monitoring.
Research Innovation: The two companies will jointly explore advancements in elastography and quantitative imaging, with a focus on accelerating the development and clinical adoption of precision liver care technologies.
Executive Perspectives
“This strategic collaboration with Hisky Medical marks a milestone for GE HealthCare in China,” said Ye Yongmei, Vice President, Treasurer, and General Manager of Business Development at GE HealthCare China. “It reflects our commitment to expanding access to precision liver care and addressing the high prevalence of fatty liver disease with scalable, integrated solutions.”
“Fatty liver disease is a growing public health challenge,” said Shao Jinhua, Chairman of Hisky Medical. “By combining our diagnostic expertise with GE HealthCare’s global technology leadership, we aim to raise the standard of care and expand access to advanced liver disease solutions, especially in community healthcare settings.”
Chen Chuhui, Vice President of GE HealthCare China and General Manager of the Advanced Visualization Solutions (AVS) business, added: “Ultrasound is the first line of defense in liver disease diagnosis. Our Wuxi Innovation Center — GE HealthCare’s largest global ultrasound manufacturing base — is a hub for collaborative innovation. This partnership with Hisky Medical will accelerate the development of integrated solutions not only for liver disease but also for broader digestive health applications.”